EGFR 19 Del的晚期非小细胞肺癌患者一线服用EGFR-TKIs的无进展生存期长于EGFR L858R患者  

Patients with Exon 19 Deletion Were Associated with Longer Progression-Free Survival Compared to Those with L858R Mutation after First-Line EGFR-TKIs for Advanced Non-Small Cell Lung Cancer

作　　者：黄诚[1] 林根[1] 雷源源[2] 

机构地区：[1]福建省肿瘤医院肿瘤内科,福州350014 [2]广东省人民医院肿瘤中心,广东省医学科学院,广东省肺癌研究所,广州510080

出　　处：《循证医学》2015年第1期25-28,共4页The Journal of Evidence-Based Medicine

摘　　要：1文献来源Zhang YX,Sheng J,Kang SY,et al.Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer：A meta-analysis[J].PLo S One,2014,9（9）：e107161.2证据水平1a。

关 键 词：非小细胞肺癌 EGFR突变 表皮生长因子受体酪氨酸激酶抑制剂 无进展生存期 

分 类 号：R734.2[医药卫生—肿瘤]